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Abstract
DNA damage triggers a network of signaling events that leads to cell cycle arrest or apoptosis. This DNA damage response
acts as a mechanism to prevent cancer development. It has been reported that fatty acids (FAs) synthesis is increased in
many human tumors while inhibition of fatty acid synthase (FASN) could suppress tumor growth. Here we report that
saturated fatty acids (SFAs) play a negative role in DNA damage response. Palmitic acid, as well as stearic acid and myristic
acid, compromised the induction of p21 and Bax expression in response to double stranded breaks and ssDNA, while
inhibition or knockdown of FASN enhanced these cellular events. SFAs appeared to regulate p21 and Bax expression via Atr-
p53 dependent and independent pathways. These effects were only observed in primary mouse embryonic fibroblasts and
osteoblasts, but not in immortalized murine NIH3T3, or transformed HCT116 and MCF-7 cell lines. Accordingly, SFAs showed
some positive effects on proliferation of MEFs in response to DNA damage. These results suggest that SFAs, by negatively
regulating the DNA damage response pathway, might promote cell transformation, and that increased synthesis of SFAs in
precancer/cancer cells might contribute to tumor progression and drug resistance.
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Introduction
Numerous studies have implicated that fatty acids, fat diet, and
obesity play a role in cancer development [1–3]. Fatty acids are
the building blocks of fat and exist either in free forms or
components of triacylglycerol, phospholipids, and cholesterol. In
serum, the concentration of free fatty acids is .500 mM under
normal conditions and .1200 mM under fasting, with palmitic
acid accounting for 28% [4,5]. They can be obtained from the diet
fat or synthesized in the cells, especially in lipogenic tissues such as
liver, adipose, and lactating breast. Fatty acids are synthesized by
FASN using malonyl-CoA and acetyl-CoA as substrates. For
people with a balanced diet, de novo fatty acid synthesis is
insignificant and FASN protein level is very low in lipogenic as
well as other tissues. FAs play important roles in energy storage,
membrane structure, protein acylation, signal transduction, and
regulation of gene transcription [6].
However, cancer cells, especially of the breast, prostate, colon,
ovary, endometrium, and thyroid origin, express very high levels
of FASN and this up-regulation is under the control of aberrant
MAPK and PI-3K-Akt signaling [2,7–9]. FASN is also expressed
in early stages of tumor development or pre-cancer lesions such as
colonic adenoma, dysplastic squamous epithelium, and carcinoma
of the tongue, although this up-regulation is more pronounced in
the late stages of tumors. Moreover, FASN can be detected in the
serum of these patients and this can be used as a diagnostic
marker. De novo synthesized fatty acids account for more than 90%
of the triacylglycerol in tumor cells [10]. Exacerbated FAs
metabolism is believed to play an important role in cancer
pathogenesis by conferring proliferating advantage [1].
FASN is now becoming a drug target for cancer therapy. It has
been found that cerulenin, a natural fungal inhibitor of FASN,
specifically targets and suppresses tumor cell growth, with little
effect on the surrounding normal tissues [11]. A small compound,
called C75, has a similar efficacy on FAs synthesis and anti-tumor
activity [12]. These compounds inhibit cell cycle progression and
causes apoptosis [13]. These effects seem to be mediated by FAs
synthesis. However, how inhibition of FASN suppresses tumor
growth remains unclear. Another question is the roles of increased
synthesis of FAs in tumorigenesis.
DNA damage is generated by exogenous agents such as ionizing
radiation (IR), ultraviolet (UV) light exposure, genotoxic com-
pounds including chemotherapeutic drugs such as adriamycin,
and endogenous factors such as reactive oxygen species which are
generated by mitochondria in the process of b-oxidation.
Depending on the types and the severity of DNA lesions, cells
respond to DNA damage by undergoing cell cycle arrest or
apoptosis when the damage is beyond repair [14].
DNA damage activates multiple signaling cascades. At the
center of the signaling network are phosphoinositide-3-kinase-like
kinases (PIKKs) that include DNA-PKcs, Atm, and Atr, all of
which are exclusive serine/threonine kinases [15]. Atm responds
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single stranded DNA (ssDNA), stalled DNA replication and UV-
induced damage. DSBs alter the chromatin structures and induce
rapid intermolecular phosphorylation of Atm on Ser1981, leading
to dissociation of the previously inert dimer complex and
activation of Atm. Activated Atm initiates cell signaling events to
induce cell cycle arrest or apoptosis through phosphorylation of
p53 at Ser15 and up-regulation of p21 or Bax and Puma [16].
Later, DSBs can be converted to ssDNA during repair, where Atr
is recruited and activated [17]. Activated Atr can phosphorylate
p53 and Chk1 to regulate cell cycle and apoptosis.
Many of the proteins involved in DNA damage response are
found to promote cancer development when mutated [18].
Furthermore, it was recently reported that in many cell types,
the conversion from pre-cancer to cancer is accompanied by
activation of the DNA damage response, which ceases to exist
once converted to cancer cells [19,20]. The function for this
activation is to inhibit cell proliferation or to induce apoptosis. As a
result, cells with mutations in proteins involved in DNA damage
response are selected and become cancerous. Thus, DNA damage
response acts as a protective mechanism against cancer develop-
ment [16]. Since FASN expression is up-regulated and FAs levels
are increased in precancer as well as cancer cells, we studied the
role of SFAs in DNA damage response by checking p53
accumulation, p21 and Bax induction, and cell growth. We found
that the presence of SFAs compromised cell response to DNA
damage in primary cells but not in immortalized or transformed
cells, at a step upstream of p53 and Chk1, likely Atr. Moreover,
the observation that SFAs have a more dramatic effect on p21 and
Bax induction than on p53 phosphorylation and stabilization in
response to DNA damage and that SFAs could regulate p21 and
Bax expression in the absence of genotoxic stress suggests that
SFAs also control p21 and Bax expression through other
pathway(s) in addition to Atr-p53. These results support the
concept that increased FAs synthesis might promote tumorigenesis
by downplaying the DNA damage response pathway.
Results
A negative role for SFAs in DNA damage response in
primary MEFs
Since DNA damage response plays an important role in
preventing tumorigenesis and FAs synthesis is greatly enhanced in
pre-cancer/cancer cells, we attempt to test whether SFAs affect
DNA damage response. We first tested palmitic acid, the most
abundant SFA in serum, the end-product of de novo fatty acid
synthesis, and a substrate for lipid synthesis and protein palmitoyla-
tion. Primary mouse embryonic fibroblasts (MEFs) were used since
they show good response to DNA damage induced by adriamycin, a
chemotherapeutic drug that has been proved to cause both DSBs
and ssDNA. Treatmentof MEFswith differentdoses of palmiticacid
(50, 100, 200, 300 mM) revealed that palmitic acid was toxic to the
cells at concentrations over 200 mM (data not shown). Therefore,
100 mM of palmitic acid was used throughout this study. We also
found that palmitic acid itself slightly down-regulated the basal levels
of p21 and Bax in MEFs (Fig. 1A), suggesting that palmitic acid can
also regulate the expression of these molecules via pathways that are
not activated by DNA damage. Moreover, palmitic acid significantly
inhibited adriamycin-induced up-regulation ofp21, Bax, and p53, as
well as phosphorylation of p53 on Ser15 (Fig. 1A). However, we
found that palmitic acid showed no effect on adriamycin-induced
nuclear foci formation of H2AX (Fig. 1B), an indication of the extent
of DNA damage. These results suggest that palmitic acid acts at a
step upstream of p53 but downstream of foci formation. Further-
more, we found that palmitic acid showed a more dramatic effect on
p21 and Bax induction than on p53 phosphorylation and
stabilization (Fig. 1A), confirming that palmitic acid could also
regulate p21 and Bax induction in a p53 phosphorylation/
stabilization independent manner.
In order to investigate whether this effect is palmitic acid
specific, we then tested other saturated fatty acid stearic acid (C18)
and myristic acid (C14), both of which are present in the serum
with stearic acid accounting for close to 13 % of the total FAs [5].
We found that pretreating MEFs with either stearic acid or
myristic acid, at 100 mM, also compromised adriamycin-induced
p21 and Bax induction, p53 phosphorylation, and p53 accumu-
lation (Supplemental Fig. S1). These results suggest that SFAs play
a rather general role in cell response to DNA damage.
Another genotoxic stress reagent hydroxyurea (HU), which
generates ssDNA and activates Atr, was used to confirm this finding.
As expected, HU could induce p21 expression and p53 accumula-
tion in primary MEFs (Fig. 2A). Pretreatment with palmitic acid
impeded p53 and p21 up-regulation, especially at late time point,
without affecting hydroxyurea induced nuclear foci formation
(Fig. 2A and 2B, and Supplemental Fig. S2A). These results support
a role for palmitic acid in cell response to ssDNA. IR, which initially
generates DSB and rapidly activates Atm, and later ssDNA in the
subsequent repair process and activates Atr [17], was also examined.
In general, we found that palmitic acid pretreatment inhibited p53
phosphorylation and up-regulation of p53, p21, and Bax, notably at
later time points, without affecting nucleus foci formation (Fig. 2C,
Supplemental Fig. S2B, and data not shown). These results suggest
that SFAs might have a more prominent effect on Atr. Surprisingly,
we found that palmitic acid treatment also led to a quicker induction
of p21 in response to IR (compare the 1, 2, 6 hr treatment of
adriamycin in Fig. 2C). The discrepancy between p53 phosphory-
lation/stabilization and p21 induction confirms that palmitic acid
can regulate p21 expression in p53 independent manner.
In support of this notion, we also found that adriamycin-
induced Atm activation was not significantly altered by pretreat-
ment with palmitic acid in MEFs (Fig. 3A and Supplemental Fig.
S3A). Since DNA damage-induced foci and the activation of Atm
are indications of the extent of DNA damage, we believe that the
presence of SFAs do not have an effect on the amounts of
damaged DNA generated by adriamycin treatment. On the
contrary, phosphorylation of Atr was reduced in the presence of
palmitic acid at the basal level or in response to adriamycin
treatment. In accordance, Chk1 phosphorylation at Ser317, a
substrate specific for Atr, was also reduced (Fig. 3A and
Supplemental Fig. S3A). This is consistent with the observation
that HU-induced DNA damage response was negatively regulated
by SFAs (Fig. 2A) and that IR-induced Chk1 phosphorylation was
also diminished in palmitic acid pretreated cells (Fig. 3B and
Supplemental Fig. S3B). Moreover, inhibition of Atm and Atr with
caffeine blocked adriamycin induced up-regulation of p21, Bax,
p53, and p53 phosphorylation (Supplemental Fig. S4). Treatment
with both caffeine and palmitic acid gave rise to similar results as
caffeine alone (Supplemental Fig. S4). These results suggest that
Atm and Atr are essential for the DNA damage response under
our experimental settings and that SFAs’ effect on DNA damage
response is likely to be mediated by Atm and Atr, especially Atr
(based on Fig. 3). Further investigation is needed to understand the
mechanisms by which palmitic acid regulates the activation of Atr.
Inhibition of fatty acid synthase enhanced p21 induction
and p53 accumulation
To further substantiate the conclusion that SFAs have an
influence on DNA damage response, we inhibited FA synthesis by
FAs in DNA Damage Response
PLoS ONE | www.plosone.org 2 June 2008 | Volume 3 | Issue 6 | e2329Figure 1. SFA inhibited adriamycin-induced p53 activation and induction of p21 and Bax in MEFs. A. MEFs were pretreated with 100 mM
of palmitic acid (PA) for 16 hrs and then stressed with adriamycin for different periods of time. Cells were collected and the protein levels of p53, p21,
Bax, and b-Actin and the level of phospho-p53 (Ser15) were determined by Western blot analysis. Bottom panels: quantitation data. The values of
signals at different time points were normalized to that of time 0, which were set at 1.0 without SFA treatment. Asterisks mark samples significantly
different from the control group at the same time point with P,0.05. B. Palmitic acid showed no effect on adriamycin-induced nuclear foci assembly
of H2AX. MEFs were pretreated with palmitic acid overnight, then with adriamycin for 8 hrs, and immuno-stained for endogenous H2AX. Counting
the number of foci revealed no significant difference between PA-treated and untreated cells.
doi:10.1371/journal.pone.0002329.g001
FAs in DNA Damage Response
PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2329adding FASN inhibitors and then checked DNA damage response.
MEFs were pretreated with 1 mg/ml C75 or cerulenin, which have
been shown to inhibit fatty acid synthesis in human or mouse
fibroblasts [11,23–25], and then challenged with adriamycin. It
was found that C75 or cerulenin markedly enhanced p-Atr, p21/
Bax induction, p53 phosphorylation, and p53 accumulation
(Fig. 4A and Fig. S5A), with C75 exhibiting a stronger effect than
cerulenin. Such a difference between these two inhibitors has been
previously reported [26,27]. Moreover, these findings were also
confirmed by the FASN knockdown experiments (Fig. 4B and Fig.
S5B). FASN was knocked down in MEFs with pooled shRNA.
When treated with adriamycin, these cells showed enhanced
induction of p21, Bax and p53, and phosphorylation of p53
(Fig. 4B). These results suggest that lowering SFA had a positive
effect on this response, which further supports that SFAs play a
negative role in DNA damage response. It is predictable that up-
regulated expression of FASN and increased levels of FAs
observed in different cancer types would compromise cell response
to DNA damage, thus promoting tumorigenesis. It has been
previously reported that C75 could trigger DNA damage response
by activating p53 and inducing p21 expression [28]. However, we
found that the levels of p53 and p21 did not markedly change in
the presence of C75 or cerulenin in MEFs (Fig. 4A).
SFAs also impaired cell response to DNA damage in
primary osteoblasts
In order to exclude a cell type specific effect, we also tested
primary osteoblasts that were freshly isolated from the calvaria of
new born pups or fetuses. These cells are of bone marrow
mesenchymal stem cell origin. It was found that these cells
responded to adriamycin treatment to a similar extent as primary
MEFs, justified by increased expression of p21 and accumulation
of p53. Similarly, pretreatment of these cells with palmitic acid
compromised p21 and Bax induction and p53 phosphorylation
(Fig. 5A and Supplemental Fig. S6A), suggesting that the function
for SFAs in DNA damage response is also applicable to primary
osteoblasts. However, palmitic acid treatment showed an insignif-
icant effect on the protein levels of p53 in response to adriamycin
(Fig. 5A). This could be due to a cell type specific effect on p53
stabilization. Stabilization of p53 can also be regulated by other
proteins such as Atf3, which is induced by DNA damage via
MAPK pathways [29].
SFAs showed no inhibitory effect on DNA damage
response in immortalized NIH3T3 and cancer cell lines
MCF-7 and HCT116
We also expanded our study to include immortalized and tumor
cell lines. NIH3T3 cells appear to be a good match for primary
MEFs as they share the same origin. Upon DNA damage,
NIH3T3 showed response to DNA damage through induction of
p21 and accumulation of p53, even though phosphorylation of
Figure 2. Hydroxyurea and ionizing radiation-induced DNA
damage response was also inhibited by palmitic acid in MEFs.
A. MEFs were pretreated with 100 mM of palmitic acid (PA) for 16 hrs
and then stressed with 5 mM hydroxyurea (HU) for different periods of
time. Cells were collected and the protein levels of p53, p21, Bax, p-p53,
and b-Actin were determined by Western blot analysis. B. Palmitic acid
showed no effect on hydroxyurea-induced nuclear foci assembly of
H2AX. MEFs were pretreated with palmitic acid overnight, then with
hydroxyurea for 8 hrs, and immuno-stained for endogenous H2AX.
Counting the number of foci revealed no significant difference between
PA-treated and untreated cells. C. Similar experiment was carried out
except that DNA damage was induced by 10 Gy IR.
doi:10.1371/journal.pone.0002329.g002
Figure 3. SFA inhibited phosphorylation of Atr and Chk1 in
MEFs. A. MEFs were pretreated with 100 mM of PA for 16 hrs and then
stressed with adriamycin for different periods of time. Cells were
collected and the protein levels of Atm, phospho-Atm, Atr, phospho-
Atr, Chk1, and phospho-Chk1 were determined by Western blot
analysis. B. Similar experiment was carried out except that DNA
damage was induced by 10 Gy IR.
doi:10.1371/journal.pone.0002329.g003
FAs in DNA Damage Response
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pretreating the cells with palmitic acid showed little effect on the
protein levels of Bax, p21 and p53, and p53 phosphorylation in
response to adriamycin. Moreover, in this cell line, SFAs hardly
showed any effects on hydroxyurea-induced DNA damage
response either (data not shown). We tried to use other
immortalized MEFs to confirm this finding. Unfortunately, we
were unable to get any immortalized MEFs that do not have
mutations in p53 (data not shown). We then tried human breast
cancer cell line MCF-7 that is shown to express high levels of
FASN [9]. Palmitic acid or myristic acid treatment showed little
effect on adriamycin induced p53 phosphorylation or p53 up-
regulation. Yet we observed an increase in the basal levels of p21
and Bax in the presence of palmitic acid or myristic acid.
Adriamycin treatment did not further induce the expression of p21
and Bax (Fig. 5C and Fig. S6C). This confirms that SFAs might
regulate p21 and Bax in the absence of DNA damage.
We further examined this on human colon cancer cell line
HCT116 that expresses wild type p53. This cell line has been
shown to highly express fatty acid synthase and likely to contain
high levels of FAs [9]. It also responded well to adriamycin in
terms of p53 accumulation and p21 induction. However, unlike
primary cells, pretreatment of these cells with palmitic acid or
stearic acid did not inhibit the induction of p21 or Bax, instead, a
slightly enhanced induction was observed for p21 (Figs. 6A, 6B,
S7A and S7B). Moreover, palmitic acid, even at 200 mM, a dosage
showing toxic effect in HCT116 cells, failed to repress adriamycin-
Figure 4. Inhibition of fatty acid synthesis with Cerulenin and
C75 enhanced DNA damage response in MEFs. A. MEFs were
pretreated with 1 mg /ml of Cerulenin (Ceru) or C75 for 16 hrs and then
stressed with adriamycin for different periods of time. Cells were collected
and the protein levels of p53, p21, Bax, and b-Actin and the level of
phospho-p53 (Ser15) were determined by Western blot analysis. Bottom
panels: quantitation data (fold induction). B. Knockdown of FASN with
shRNA showed increased p53 phosphorylation and induction of p21 and
Bax in response to adriamycin. Asterisks mark samples significantly
different from the control group at the same time point with P,0.05.
doi:10.1371/journal.pone.0002329.g004
Figure 5. Murine primary osteoblasts, NIH3T3, and MCF-7
showed different responses to the effects of SFA. Primary
calvarial osteoblasts (A), NIH3T3 (B), and MCF-7 (C) cells were pretreated
with 100 mM of PA or MA for 16 hrs and then stressed with adriamycin
for different periods of time. Cells were collected and the protein levels
of p53, p21, Bax, and b-Actin and the level of phospho-p53 (Ser15) were
determined by Western blot analysis.
doi:10.1371/journal.pone.0002329.g005
FAs in DNA Damage Response
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S7C). These results confirmed that SFAs differentially regulate
DNA damage response in primary and transformed cells. We then
tried FASN inhibitor C75 in HCT116 cells. It was found that C75,
at 1 or 5 mg/ml, enhanced the up-regulation of p21, Bax, and p53,
without affecting p53 phosphorylation on Ser15 (Supplementary
data Fig. S8). This is consistent with a previous study showing that
pharmacological inhibition of FASN induced p53 and p21 up-
regulation in RKO colon carcinoma cells [28]. Therefore,
although HCT116 cells behaved differently from primary MEFs
in the presence of SFAs, they seem to respond to FASN in a
similar way. This discrepancy between primary cells and
immortalized/transformed cells could be due to the high levels
of de novo synthesized FAs.
SFAs promoted cell proliferation in the presence of
adriamycin
DNA damage is known to induce cell cycle arrest and/or
apoptosis. We found that palmitic acid had little effect on the
distribution of G1, S, and G2 phases, in the presence or absence of
adriamycin, suggesting that its effect on cell cycle checkpoints is
minimal (data not shown). On the other hand, several studies have
reported that SFAs, especially palmitic acid, could regulate
apoptosis. In some cases such as pancreatic cells, palmitic acid
induces cell death through mtDNA damage and genomic DNA
damage [30,31], probably due to the reactive oxygen species
generated during beta-oxidation of acetyl-CoA. However, we did
not observe a DNA damage response upon palmitic acid treatment
(Fig. 1). Other reports also state that palmitic acid induces apoptosis
by down-regulating cardiolipin, a phospholipid that helps the
insertion and retention of cytochrome C into the mitochondria
membrane. In contrast, it has also been reported that inhibition of
FASN reduced both the level of palmitic acid and apoptosis, and
exogenously added palmitic acid helped to protect the cells [32]. To
test whether SFAs have an effect on adriamycin-induced cell death,
MEFs were pretreated with 100 mM SFAs for 16 hrs and then
challenged with 0.1 mM adriamycin for different periods of time.
Cell proliferation/survival rates were measured with WST-1 assay.
Under this setting, SFAs pretreatment could only slightly inhibit
adriamycin-induced cell death (Fig. 7A). Interestingly, we found that
cells could recover after prolonged treatment, and that cells
pretreated with SFAs appeared to proliferate at an increased rate
compared to the untreated cells (Fig. 7A). Adriamycin, even at
0.1 mM, was able to induce the expression of p21and Bax, and the
stabilization of p53, although Ser15 phosphorylation was hardly
detectable (Fig. 7B and data not shown). When 0.5 mMo f
adriamycin was applied to the cells, the stimulatory effects of SFAs
on proliferation were less obvious (Supplementary data Fig. S9),
likely due to thetoxic effectof adriamycin.Moreover,C75, aswell as
cerulenin, induced cell death in MEFs. A combination of C75 with
0.1 mM of adriamycin resulted in increased cell death rates (Fig. 7C
and data not shown). This findingis consistent with previous findings
that FASN inhibitor could induce cell death and that these cells
could be rescued by addition of FAs [33,34].
Discussion
Our studies indicate that SFAs could compromise DNA
damage-induced cell response in primary cells but not in
immortalized cells. Pretreatment with palmitic acid, myristic acid,
or stearic acid leads to reduced accumulation of p53, reduced
induction of p21 and Bax, diminished activation of Chk1, and
improved cell proliferation. Moreover, inhibition of FAs synthesis,
with pharmacological inhibitors or knock-down of FASN,
enhanced the induction of p21 and Bax and accumulation of
p53. Based upon the fact that the levels of FASN expression and
FA synthesis are dramatically increased in the pre-cancer stages,
and that DNA damage response occur during the transition from
precancerous to cancer, we propose that the increased levels of
FAs might modulate cell response to DNA damage, leading to
defects in cell cycle checkpoints and apoptosis. Compromised
DNA damage will likely result in accumulation of DNA lesions
and eventually facilitate tumorigenesis. This concept is also
supported by the observation that overexpression of FASN is
correlated with high degree of microsatellite instability in
colorectal cancer independent of CpG island methylator pheno-
types [35]. The actions of SFAs in DNA damage response might
also be one of the mechanisms underlying the association between
high fat diet/obesity and tumorigenesis [36]. Cells with active fatty
acids metabolism might have defect in cell cycle arrest or apoptosis
in response to genotoxic stress. The predominant cancers
associated with obesity are breast, prostate, endometrium, colon,
Figure 6. SFA did not repress the DNA damage response in
HCT116 cells. A. HCT116 cells were pretreated with 100 mM of PA for
16 hrs and then stressed with adriamycin for different periods of time.
Cells were collected and the protein levels of p53, p21, Bax, and b-Actin
and the level of phospho-p53 (Ser15) were determined by Western blot
analysis. B. The effect of SA in HCT116 cells. C. Palmitic acid, even at
200 mM, did not repress adriamycin-induced p-53 phosphorylation or
induction of p21 and Bax.
doi:10.1371/journal.pone.0002329.g006
FAs in DNA Damage Response
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high levels of FASN [37]. Noteworthy is that the correlation
between high fat diet and increased risk for tumorigenesis is still
controversial except in ovarian cancer [38].
DNA damage response is controlled by signaling pathways
started from the DNA damage-induced foci, which are believed to
be DNA repair centers. Many proteins were accumulated at the
foci including the signaling molecules Atm and Atr, which
phosphorylate p53, Mdm2, Chk1/2 and other molecules to
regulate cell cycle control and apoptosis. Since SFAs interfered
with p53 phosphorylation, p53 accumulation, induction of p53
target genes such as p21 and Bax, and phosphorylation of Chk1,
we conclude that SFAs act at a rather early step of the signaling
cascade. Since foci formation is not affected, SFA is likely to act at
a step affecting Atm/Atr activation, or adaptor proteins that
recruit effectors such as p53 and Chk1/2 to the foci, or both. We
found that SFAs had a more profound effect on Atr phosphor-
ylation and activation of Chk1, implying that SFAs might mainly
regulate the activation of Atr and/or the phosphorylation of Atr
targets. But how do SFAs execute their function on Atr? In view of
this, there are a few possibilities. Firstly, SFAs might alter the
synthesis of phospholipids, which are known to regulate signaling
events. A recent study showed that a shift of phosphatidylcholine
chains from polysaturated fatty acids to polyunsaturated fatty acids
activates p53 Ser15 phosphorylation through Atr [39]. Secondly,
as shown for transcription factors PPAR and LXR, SFAs and their
metabolic intermediates might interact directly with signaling
molecules. Thirdly, SFAs especially palmitic acid, as well as their
metabolic intermediate acetyl-CoA, can be directly used as
substrates to modify proteins, in the forms of palmitoylation and
acylation. Protein palmitoylation has been shown to affect
enzymatic activity, protein trafficking, or protein stabilization
[40,41]. In addition, it appears that in response to genotoxic stress,
SFAs have a more dramatic effect on the induction of p21 and Bax
than on p53 phosphorylation and stabilization. It was also found
that in some cell types, SFA could regulate the expression of p21
and Bax in the absence of genotoxic stress. Therefore, SFAs
regulate the Atr-p53-p21/Bax pathway at more than one step.
Further investigation is needed to understand the mechanisms by
which SFAs regulate cell response to DNA damage.
One intriguing finding is that while primary cells’ response to
DNA damage is repressed by SFAs, immortalized/transformed cells
show resistance to this effect. One possible explanation is that
immortalized/transformed cells have acquired some changes in the
gene expression patterns, in order to adapt to the long term presence
ofelevatedlevelsofFASNandfattyacids.Sotheywillnotrespond to
further increases in SFAs. The second possibility is that the
immortalized/transformed cells might have acquired mutations in
the proteins that link fatty acids to the DNA damage response and
repair pathways, e.g., proteins involved in DNA damage response
that can bind or be modified by SFAs. The observation that both
primary and transformed cells are responsive to FASN inhibition in
genotoxic stress favors the first hypothesis as genetic changes are
usually irreversible. Another interesting finding is that SFAs only
modulate cell survival and proliferation in response to low dose of
adriamycin, which might reflect the in vivo condition, where the
nutrients SFAs modulate cell response to modest DNA damage
generated by endogenous factors such as ROS. These results also
suggest that SFAs may play a minimal role in DNA damage caused
by high dose of genotoxic agents.
Inhibitors of FASN have been found to induce apoptosis in
cancer cells that have high levels of FASN. These include breast,
prostate, colon, and lung cancers. Based upon our findings that an
increase in SFA levels compromises DNA damage response while
inhibition of FAs synthesis enhances these cellular events, lowering
the cellular level of FAs might reduce the risks of cancer
development. In addition, lowering the cellular level of FAs might
also improve the efficacy of radiotherapy and chemotherapy with
genotoxic drugs. Some chemotherapeutic drugs such as cyclo-
phosphamide, busulfan, cisplatin, and mitomycin cause inter-
strand and/or intrastrand crosslinks, while some, e.g., irinotecan
and dactinomycin, affect DNA unwinding and therefore DNA
replication [42,43]. Radiotherapy with ionizing radiation gener-
ates DSBs, which are later converted to ssDNA. These treatments
kill the cancer cells or stop their proliferation, at least partially, by
activating the DNA damage response. However, in the presence of
elevated levels of FAs, the DNA damage response is compromised,
Figure 7. SFA showed an inhibitory effect on adriamycin-
induced cell death. A. MEFs were pretreated with 100 mM of PA, MA,
or SA for 16 hrs and then stressed with 0.1 mM adriamycin for different
periods of time. The number of viable cells was determined by WST-1
assay. The experiments were repeated three times. B. Adriamycin, at
0.1 mM, was able to activate DNA damage response pathway. C.
Adriamycin and C75 showed a synergistic effect in inducing cell death
in MEFs. Asterisks mark samples significantly different from the control
group at the same time point with P,0.05.
doi:10.1371/journal.pone.0002329.g007
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combinational use of these genotoxic drugs or radiotherapy with
inhibitors for FASN might be beneficial, at least for pre-cancer
cells when the DNA damage response pathway is still intact.
Materials and Methods
Isolation and culture of MEFs and calvarial osteoblasts
Mouse embryonic fibroblasts were prepared as previously
described [21]. To prepare primary osteoblasts, calvaria from
19–20 day old fetuses or new born pups were isolated, washed in
PBS and digested in MEM alpha medium containing collagenase
type V and trypsin for 10 min at 37uC four times. The supernatant
from the first digestion was discarded and supernatants from the
last three digestions were pooled. The cells were washed and
plated onto 6 well plates and grown in MEM alpha medium
supplemented with 15% FCS (HyClone) and glutamine until
confluent [21]. The osteoblast cultures were amplified to passage 3
before being used in further experiments. MEFs, HCT116, MCF-
7, and NIH3T3 were cultured in DMEM supplemented with 10%
FCS and penicillin/streptomycin in humidified atmosphere of 5%
CO2 at 37uC.
DNA damage
DNA damage was generated with genotoxic stress. 0.1–1 mM
adriamycin, 10 Gy of gamma-radiation, or 5 mM hydroxyurea
was used to treat different cells for different periods of time. To test
the effect of SFAs or FASN inhibitors on DNA damage response,
different concentrations of palmitic acid, myristic acid, stearic acid
(Sigma, USA), or Cerulenin or C75 (Cayman Chemical, USA)
were added to the cultures before the addition of DNA damage
reagents. Briefly, for SFAs treatment, 100 mM of SFAs were
included in the culture medium for overnight. The cells were then
treated with adriamycin or hydroxyurea for different periods of
time before being harvested for further experiments. To inhibit
FASN, C75 or Cerulenin were included in the culture medium for
24 hrs. The cells were further treated with adriamycin or
hydroxyurea. To knock down FASN, SiGenome ON-TARGET
plus SMART pool duplex of FASN were purchased from
DHARMACON (Cat# L-040091).
Western blot analysis
Cells were washed with cold PBS and lysed in RIPA buffer
containing 1 mM sodium orthovanadate, 1 mM NaF, and
protease inhibitors. Protein concentration was determined by the
Bio-Rad assay. For immunoblotting, proteins were resolved by
SDS-PAGE and were transferred to PVDF membranes (Milli-
pore), followed by incubation with primary and secondary
antibodies and detected by ECL kit (Amersham Biosciences)
[22]. The following antibodies were used in this study: b-actin
(Sigma), phospho-Chk1 (Ser345), phospho-p53 (Ser15), phospho-
Atr (Ser428), Chk1, FANS, and p53 (Cell Signaling), phospho-
Atm (Ser1981) (Rockland), Atm and Atr (Gene Tex), H2AX
(Bethyl Lab), p21 and Bax (Biochem Diagnostic).
Cell viability analysis
To measure cell death rates, cells were plated in 96 well plates at
1610
4/well, and then treated with fatty acids or FASN inhibitors
for 24 hrs, followed by adriamycin for different periods of time.
Cell proliferation reagent WST-1 (Roche) was added to each well
and the cells were further incubated for 3 hour at 37uC. The
absorbance was measured against a background control by
microplate (ELISA) reader at 430 nm. The reference wavelength
is 650 nm.
Immunofluorescence staining
Cells were grown overnight on glass cover-slips, subjected to
adriamycin or hydroxyurea treatment, and were fixed with 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100 for
20 min, blocked with 5% BSA for 30 min, and then incubated
with anti-H2AX antibodies and FITC-conjugated secondary
antibodies. The number of foci was counted under confocal
microscope.
Statistical analysis
Statistical analysis was performed using Student’s unpaired t-test
(STATISTICA).
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